Ocular manifestations of multiple myeloma

Observing ocular toxicity

Variable corneal adverse events

Management strategies for patients

Open line between ophthalmology and oncology

Overcoming collaborative challenges

How ophthalmologists educate themselves

Videos

Shaily Shah, MD, and Esen Karamursel Akpek, MD, discuss managing the potential ocular toxicities that can occur with belantamab mafodotin-blmf in patients with relapsed/refractory multiple myeloma, as well as the collaborative role between ophthalmologists and oncologists.

Managing ocular toxicities in myeloma  

From patient care and treating glaucoma to the ongoing pandemic, ophthalmologists share the most pressing thoughts of concern leaving them awake at night.

What keeps ophthalmologists up at night: Part III

COVID-19

Video Series